Inquadramento diagnostico e gestione farmacologica della depressione senile

Translated title of the contribution: Assessment and pharmacological management of elderly depression

A. C. Altamura, E. Cattaneo, S. Pozzoli, R. Bassetti

Research output: Contribution to journalArticle

Abstract

Late-life depression is chronic and disabling and is an important factor for elderly suicide. The prevalence of depression in the elderly has attracted extensive research effort and yelded a wide range of estimates, depending on diagnostic criteria, the method of detecting depression, the experience of the interviewers and, most importantly, the characteristics of this population. Major Depression appears to be less common in the elderly than in younger adults, but subsyndromal depression is more prevalent. DSM diagnostic criteria require either depressed mood or loss of interest, but these symptoms appear to be less prominent in the elderly, being anxiety, irritability and physical symptoms more significant indicators of elderly depressive states. Depression in the elderly is essentially heterogeneous and has a multifactorial etiopathogenesis (Fig. 1): this has contributed to its underrecognition, underestimation and undertreatment. The "atypical"clinical presentation of depression in the elderly as somatic symptoms, anxiety, changes in functional ability, loss of capacity to enjoy life or loss of interest in usual activities, can be misleading for the clinician and masks an underlying mood disorder. Even "pseudodementia" is clinically important since it may result in failure to recognize and treat either depression or dementia. Comorbidity with a physical illness such as cardiovascular disease or other psychiatric symptoms (e.g. anxiety) is frequent in late-life depression, and the presence of one or more medical illnesses may influence the diagnosis of depression; moreover, it represents a negative prognostic factor for response to antidepressant therapy. The pharmacological management of depression in late life is complicated by physiological changes associated with aging (Fig. 2), higher sensitivity to develop side-effects, concomitant medical disorders with drug-drug interaction phenomena and compliance problems. These factors need to be carefully taken into account when selecting antidepressants for the treatment of depressive states in the elderly. Antidepressants are as effective in the elderly as they are earlier in life. The development of newer antidepressants has focused on compounds that are better tolerated, with reduced unwanted effects and more likely to be used in long-term treatment. Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonergic/Noradrenergic Reuptake Inhibitors (SNRI), (e.g. venlafaxine) and Noradrenergic/Serotonergic Specific Antagonist (NaSSA), (e.g.mirtazapine), show a more favourable side-effects profile and appear to be more suitable for the treatment of elderly depression. In selecting the appropriate treatment, the physician should take account of concomitant illnesses and current therapies, choosing an agent with a simple once-daily regimen and a larger pharmacodynamic and therapeutic spectrum (e.g. on depressive and anxiety symptoms). However, a comprehensive management of elderly depressive states should include not only the physician, but also a psychological and psychosocial support, which appears important to explore stressors for depression and to educate patients and their families about depressive illness and its treatment.

Original languageItalian
Pages (from-to)85-92
Number of pages8
JournalItalian Journal of Psychopathology
Volume12
Issue number1
Publication statusPublished - 2006

Fingerprint

Pharmacology
Depression
Antidepressive Agents
Anxiety
Therapeutics
Factitious Disorders
Physicians
Aptitude
Serotonin Uptake Inhibitors
Population Characteristics
Masks
Mood Disorders
Drug Interactions
Suicide
Compliance
Psychiatry
Dementia
Comorbidity
Young Adult
Cardiovascular Diseases

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Inquadramento diagnostico e gestione farmacologica della depressione senile. / Altamura, A. C.; Cattaneo, E.; Pozzoli, S.; Bassetti, R.

In: Italian Journal of Psychopathology, Vol. 12, No. 1, 2006, p. 85-92.

Research output: Contribution to journalArticle

Altamura, A. C. ; Cattaneo, E. ; Pozzoli, S. ; Bassetti, R. / Inquadramento diagnostico e gestione farmacologica della depressione senile. In: Italian Journal of Psychopathology. 2006 ; Vol. 12, No. 1. pp. 85-92.
@article{3a012e9d7f884c6ea1cccb976442d498,
title = "Inquadramento diagnostico e gestione farmacologica della depressione senile",
abstract = "Late-life depression is chronic and disabling and is an important factor for elderly suicide. The prevalence of depression in the elderly has attracted extensive research effort and yelded a wide range of estimates, depending on diagnostic criteria, the method of detecting depression, the experience of the interviewers and, most importantly, the characteristics of this population. Major Depression appears to be less common in the elderly than in younger adults, but subsyndromal depression is more prevalent. DSM diagnostic criteria require either depressed mood or loss of interest, but these symptoms appear to be less prominent in the elderly, being anxiety, irritability and physical symptoms more significant indicators of elderly depressive states. Depression in the elderly is essentially heterogeneous and has a multifactorial etiopathogenesis (Fig. 1): this has contributed to its underrecognition, underestimation and undertreatment. The {"}atypical{"}clinical presentation of depression in the elderly as somatic symptoms, anxiety, changes in functional ability, loss of capacity to enjoy life or loss of interest in usual activities, can be misleading for the clinician and masks an underlying mood disorder. Even {"}pseudodementia{"} is clinically important since it may result in failure to recognize and treat either depression or dementia. Comorbidity with a physical illness such as cardiovascular disease or other psychiatric symptoms (e.g. anxiety) is frequent in late-life depression, and the presence of one or more medical illnesses may influence the diagnosis of depression; moreover, it represents a negative prognostic factor for response to antidepressant therapy. The pharmacological management of depression in late life is complicated by physiological changes associated with aging (Fig. 2), higher sensitivity to develop side-effects, concomitant medical disorders with drug-drug interaction phenomena and compliance problems. These factors need to be carefully taken into account when selecting antidepressants for the treatment of depressive states in the elderly. Antidepressants are as effective in the elderly as they are earlier in life. The development of newer antidepressants has focused on compounds that are better tolerated, with reduced unwanted effects and more likely to be used in long-term treatment. Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonergic/Noradrenergic Reuptake Inhibitors (SNRI), (e.g. venlafaxine) and Noradrenergic/Serotonergic Specific Antagonist (NaSSA), (e.g.mirtazapine), show a more favourable side-effects profile and appear to be more suitable for the treatment of elderly depression. In selecting the appropriate treatment, the physician should take account of concomitant illnesses and current therapies, choosing an agent with a simple once-daily regimen and a larger pharmacodynamic and therapeutic spectrum (e.g. on depressive and anxiety symptoms). However, a comprehensive management of elderly depressive states should include not only the physician, but also a psychological and psychosocial support, which appears important to explore stressors for depression and to educate patients and their families about depressive illness and its treatment.",
keywords = "Elderly depression, Pharmacotherapy",
author = "Altamura, {A. C.} and E. Cattaneo and S. Pozzoli and R. Bassetti",
year = "2006",
language = "Italian",
volume = "12",
pages = "85--92",
journal = "Giornale Italiano di Psicopatologia",
issn = "1592-1107",
publisher = "Pacini Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Inquadramento diagnostico e gestione farmacologica della depressione senile

AU - Altamura, A. C.

AU - Cattaneo, E.

AU - Pozzoli, S.

AU - Bassetti, R.

PY - 2006

Y1 - 2006

N2 - Late-life depression is chronic and disabling and is an important factor for elderly suicide. The prevalence of depression in the elderly has attracted extensive research effort and yelded a wide range of estimates, depending on diagnostic criteria, the method of detecting depression, the experience of the interviewers and, most importantly, the characteristics of this population. Major Depression appears to be less common in the elderly than in younger adults, but subsyndromal depression is more prevalent. DSM diagnostic criteria require either depressed mood or loss of interest, but these symptoms appear to be less prominent in the elderly, being anxiety, irritability and physical symptoms more significant indicators of elderly depressive states. Depression in the elderly is essentially heterogeneous and has a multifactorial etiopathogenesis (Fig. 1): this has contributed to its underrecognition, underestimation and undertreatment. The "atypical"clinical presentation of depression in the elderly as somatic symptoms, anxiety, changes in functional ability, loss of capacity to enjoy life or loss of interest in usual activities, can be misleading for the clinician and masks an underlying mood disorder. Even "pseudodementia" is clinically important since it may result in failure to recognize and treat either depression or dementia. Comorbidity with a physical illness such as cardiovascular disease or other psychiatric symptoms (e.g. anxiety) is frequent in late-life depression, and the presence of one or more medical illnesses may influence the diagnosis of depression; moreover, it represents a negative prognostic factor for response to antidepressant therapy. The pharmacological management of depression in late life is complicated by physiological changes associated with aging (Fig. 2), higher sensitivity to develop side-effects, concomitant medical disorders with drug-drug interaction phenomena and compliance problems. These factors need to be carefully taken into account when selecting antidepressants for the treatment of depressive states in the elderly. Antidepressants are as effective in the elderly as they are earlier in life. The development of newer antidepressants has focused on compounds that are better tolerated, with reduced unwanted effects and more likely to be used in long-term treatment. Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonergic/Noradrenergic Reuptake Inhibitors (SNRI), (e.g. venlafaxine) and Noradrenergic/Serotonergic Specific Antagonist (NaSSA), (e.g.mirtazapine), show a more favourable side-effects profile and appear to be more suitable for the treatment of elderly depression. In selecting the appropriate treatment, the physician should take account of concomitant illnesses and current therapies, choosing an agent with a simple once-daily regimen and a larger pharmacodynamic and therapeutic spectrum (e.g. on depressive and anxiety symptoms). However, a comprehensive management of elderly depressive states should include not only the physician, but also a psychological and psychosocial support, which appears important to explore stressors for depression and to educate patients and their families about depressive illness and its treatment.

AB - Late-life depression is chronic and disabling and is an important factor for elderly suicide. The prevalence of depression in the elderly has attracted extensive research effort and yelded a wide range of estimates, depending on diagnostic criteria, the method of detecting depression, the experience of the interviewers and, most importantly, the characteristics of this population. Major Depression appears to be less common in the elderly than in younger adults, but subsyndromal depression is more prevalent. DSM diagnostic criteria require either depressed mood or loss of interest, but these symptoms appear to be less prominent in the elderly, being anxiety, irritability and physical symptoms more significant indicators of elderly depressive states. Depression in the elderly is essentially heterogeneous and has a multifactorial etiopathogenesis (Fig. 1): this has contributed to its underrecognition, underestimation and undertreatment. The "atypical"clinical presentation of depression in the elderly as somatic symptoms, anxiety, changes in functional ability, loss of capacity to enjoy life or loss of interest in usual activities, can be misleading for the clinician and masks an underlying mood disorder. Even "pseudodementia" is clinically important since it may result in failure to recognize and treat either depression or dementia. Comorbidity with a physical illness such as cardiovascular disease or other psychiatric symptoms (e.g. anxiety) is frequent in late-life depression, and the presence of one or more medical illnesses may influence the diagnosis of depression; moreover, it represents a negative prognostic factor for response to antidepressant therapy. The pharmacological management of depression in late life is complicated by physiological changes associated with aging (Fig. 2), higher sensitivity to develop side-effects, concomitant medical disorders with drug-drug interaction phenomena and compliance problems. These factors need to be carefully taken into account when selecting antidepressants for the treatment of depressive states in the elderly. Antidepressants are as effective in the elderly as they are earlier in life. The development of newer antidepressants has focused on compounds that are better tolerated, with reduced unwanted effects and more likely to be used in long-term treatment. Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonergic/Noradrenergic Reuptake Inhibitors (SNRI), (e.g. venlafaxine) and Noradrenergic/Serotonergic Specific Antagonist (NaSSA), (e.g.mirtazapine), show a more favourable side-effects profile and appear to be more suitable for the treatment of elderly depression. In selecting the appropriate treatment, the physician should take account of concomitant illnesses and current therapies, choosing an agent with a simple once-daily regimen and a larger pharmacodynamic and therapeutic spectrum (e.g. on depressive and anxiety symptoms). However, a comprehensive management of elderly depressive states should include not only the physician, but also a psychological and psychosocial support, which appears important to explore stressors for depression and to educate patients and their families about depressive illness and its treatment.

KW - Elderly depression

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=33751241259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751241259&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33751241259

VL - 12

SP - 85

EP - 92

JO - Giornale Italiano di Psicopatologia

JF - Giornale Italiano di Psicopatologia

SN - 1592-1107

IS - 1

ER -